Diabetic Nephropathy Biomarker Detection and PKM2 Activator Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for diagnosing and predicting diabetic nephropathy (DN) and fail to provide adequate therapeutic solutions to prevent or treat the condition effectively.
Innovation Solution
Identification of specific proteins such as SOD1, TPI1, SORD, ALDOA, GAPDH, ENO1, FGB, SELENBP1, PEBP1, CRYL1, and PKM2 as biomarkers to diagnose and predict DN risk, along with the use of PKM2 activators to protect against DN progression by enhancing glucose metabolism pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then general diabetes monitoring is possible, but early detection of diabetic nephropathy cannot be achieved due to lack of effective biomarkers
Solution Approach 1:
The patent segments the diagnostic approach by identifying specific protein markers (SOD1, TPI1, SORD, ALDOA, GAPDH, ENO1, FGB, SELENBP1, PEBP1, CRYL1, PKM2) that can independently or collectively indicate diabetic nephropathy risk, allowing precise early detection through measurement of individual protein levels in biological samples
Solution Approach 2:
The patent introduces protein markers as intermediary substances that mediate between the pathological processes of diabetic nephropathy and detectable signals. These proteins serve as biochemical intermediaries that reflect disease state and can be measured to provide diagnostic information about early kidney damage
2Reliability
If conventional treatment methods are used, then general diabetes management is possible, but prevention or effective treatment of diabetic nephropathy cannot be achieved
Solution Approach 1:
The patent enables preliminary action by using identified protein markers to predict diabetic nephropathy risk before clinical symptoms appear. This allows intervention strategies to be implemented in advance, preventing or delaying the development of kidney complications through early risk stratification and targeted prevention
Solution Approach 2:
The patent establishes a feedback mechanism where protein marker levels provide information about disease risk and progression, allowing treatment effectiveness to be monitored and therapeutic strategies to be adjusted based on measured changes in biomarker concentrations over time
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Compositions and methods for diagnosing, predicting risk of, and/or treating diabetic nephropathy (DN).